JAK2 and breast carcinoma: Conversely, we observe that chemoresistance in breast cancer is associated with activation of JAK2-STAT pathways and that inhibition by using a FDA-approved inhibitor (Tofacitinib) of the latter pathway reverts chemoresistant cancer cells to a chemosensitive phenotype, provoking apoptosis when used in combination with doxorubicin.